Biopharmaceutical services provider expands to European market
Millipore has acquired European-based services provider BioAnaLab, extending the company&39;s biopharmaceutical services business into Europe.
Millipore has acquired European-based services provider BioAnaLab, extending the company's biopharmaceutical services business into Europe.
"Our acquisition of BioAnaLab will allow us to build on our reputation as a trusted outsource partner in North America by establishing a presence in the fast-growing European biotech market," said Jonathan DiVincenzo, president of the company’s bioscience division, in a statement. "BioAnaLab will add cGMP support testing capabilities to our portfolio, a solid customer base and a team of services professionals with expertise in emerging scientific disciplines."
BioAnaLab current offerings include assay transfer/development, validation and sample analysis and vaccine services. Millipore's experience in biomarker analytical services is expected to strengthen BioAnaLab's current offerings in that area.
More information in Millpore can be found at www.millipore.com
and on BioAnaLab at www.bioanalab.com
Metabolomics Meets Machine Learning: The Future of Nature-Inspired Drug Discovery
March 29th 2024Researchers at Enveda Biosciences are transforming nature into new medicines with their artificial intelligence (AI)-enabled industrial-scale drug discovery platform incorporating tandem mass spectrometry (MS/MS).
Element Launches New Pharmaceutical Testing Service
March 29th 2024Element Materials Technology introduced its Rapid Response Pharmaceutical Testing Service, providing expedited testing and focusing on various requirements including active ingredients and final drug products, extractables and leachables, degradation production, and elemental impurities.
